<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Khan, Aliya</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ALN Reduces Bone Turnover in Perimenopausal Women with Low BMD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Menopause-associated bone loss begins during perimenopause, ∼?2 years before the last menstrual period. This article presents data from the Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Turnover in Perimenopausal Women With Low BMD poster [ICE/ENDO 2014. Poster LBSA-0269], first study to evaluate the efficacy of an antiresorptive agent on maintaining BMD in perimenopausal women.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>